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The local delivery of small interfering RNA (siRNA) to the lungs may provide a therapeutic 
solution to a range of pulmonary disorders. Resident alveolar macrophages (rAM) in the 
bronchoalveolar lumen play a critical role in lung inflammatory responses and therefore 
constitute a particularly attractive target for siRNA therapeutics. However, achieving efficient 
gene silencing in the lung while avoiding pulmonary toxicity requires appropriate formulation 
of siRNA in functional nanocarriers. In this study, we evaluated pulmonary surfactant-coated 
dextran nanogels for the delivery of siRNA to rAM upon pharyngeal aspiration in BALB/c 
mice. Both the surfactant-coated and uncoated nanogels achieved high levels of siRNA uptake 
in rAM, yet only the surfactant-coated formulation could significantly reduce gene expression 
on the protein level. Surfactant-coated nanogels induced a profound downregulation of target 
mRNA levels, reaching 70% knockdown with ~1 mg kg-1 siRNA dose. In addition, only mild 
acute pro-inflammatory cytokine and chemokine responses were detected one day after 
nanoparticle aspiration, accompanied by a moderate neutrophil infiltration in the 
bronchoalveolar lumen. The latter could be substantially reduced by removal of excess 
surfactant from the formulation. Overall, our hybrid core-shell nanoparticles have demonstrated 
safe and effective siRNA delivery to rAM, providing a new therapeutic approach for treatment 
of inflammatory pathologies in the lung. 
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Activation of the RNA interference (RNAi) pathway by synthetic RNA duplexes, termed small 
interfering RNAs (siRNAs), enables highly efficient and sequence-specific gene silencing. The 
application of siRNAs, designed to block the expression of disease-related proteins, has 
therefore emerged as a promising therapeutic strategy for the treatment of various diseases [1-
3]. 
Pulmonary disorders, including chronic obstructive pulmonary disease (COPD) and lower 
respiratory infections, are currently amongst the top ten causes of death worldwide [4, 5]. Many 
of these diseases are characterized by an underlying inflammation. Phagocytic cells, in casu 
resident alveolar macrophages (rAM), significantly contribute to this inflammatory phenotype 
[6, 7] and thus are attractive targets for genetic interference.  
Inhalation therapy provides a non-invasive way to locally deliver high amounts of siRNA 
directly to pulmonary target cells. However, the respiratory tract imposes substantial barriers 
that need to be overcome to allow effective siRNA delivery in the target cell cytoplasm [8]. For 
instance, the cell membrane is impermeable for hydrophilic macromolecules like nucleic acids, 
precluding direct access of siRNA to the intracellular RNAi machinery. Moreover, it has been 
reported that free siRNA is more rapidly distributed to the systemic circulation upon local 
pulmonary application, which decreases the siRNA dose in the bronchoalveolar lumen [9]. To 
avoid systemic exposure and enhance cellular delivery of siRNA to target cells, siRNAs 
typically require formulation into lipid- or polymer-based drug carriers. Although it was 
previously assumed that nanoparticles are able to bypass the phagocytic uptake by rAM [10], 
recent findings illustrated that rAM preferably capture particles with a hydrodynamic diameter 
in the nanometer scale [11-13]. A multitude of novel siRNA nanocarriers has already been 
tested in vitro. Still, to date only a limited number of nanoparticles have been evaluated for 
local in vivo siRNA delivery to rAM, with variable success [14-16]. 
Earlier work by our group demonstrated that cationic biodegradable dextran nanogels (NGs) 
are promising siRNA nanocarriers in vitro. They are able to encapsulate high amounts of siRNA 
and induce a marked gene knockdown in distinct cultured cell types [17-19]. Moreover, their 
stability and biodistribution has already been evaluated upon systemic application in vivo [20, 
21]. Recently, a method has been optimized by us to combine the siRNA-loaded NGs (siNGs) 
with a clinically-approved pulmonary surfactant (Curosurf®) in a single core-shell nanoparticle, 
consisting of a siNG core layered with a pulmonary surfactant outer shell. The presence of the 
Curosurf® shell provided several beneficial traits, including improved stability and a five-fold 
enhancement of intracellular siRNA delivery in cultured lung cancer cells [22]. Given the 
significance of rAM as a target cell in many lung-related pathologies and the impressive siRNA 
delivery capacity of this hybrid core-shell nanoparticle, the key objective of this study was to 
evaluate if pulmonary surfactant-coated siNGs are equally efficient in transfecting murine rAM 
in vivo following pulmonary delivery. 
The biological efficacy of the siNGs, in the absence or presence of a pulmonary surfactant shell, 
was first investigated in a murine alveolar macrophage cell line (MH-S), using the pan-
leucocyte marker cd45 as model target gene. As the preparation of the hybrid nanoparticle 
requires an excess of pulmonary surfactant, which might influence cellular delivery and 
toxicity, we additionally sought to optimize a purification protocol for our formulation. To 
probe their suitability for in vivo siRNA delivery, BALB/c mice were treated with the distinct 
nanoparticles via pharyngeal aspiration. The cellular internalization of the (pulmonary 
surfactant-coated) siNGs and subsequent CD45 knockdown was quantified in primary rAM 
recovered from bronchoalveolar lavage (BAL) as a function of time following in vivo 
pulmonary administration. Next to efficient delivery, it is of equal importance to design delivery 
systems with an acceptable safety profile. To determine the acute local inflammatory response, 
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we quantified the expression levels of various cytokines and chemokines in the bronchoalveolar 
lumen and assessed the infiltration of inflammatory cells, one day following pharyngeal 
aspiration. 
 
2. Materials and Methods 
 
2.1. Small interfering RNAs 
Twenty-one nucleotide siRNA duplexes targeted against the protein tyrosine phosphatase 
receptor type C (CD45), hereafter abbreviated as siCD45, and non-targeting negative control 
duplexes (siCTRL) were purchased from Eurogentec (Seraing, Belgium). Both sense and 
antisense strands had a UU-overhang at the 3’-end and 5’-ends of antisense strands were 
phosphorylated. SiCD45: sense strand = 5’-GAA-GAA-UGC-UCA-CAG-AUA-A-3’; 
antisense strand = 5’-UUA-UCU-GUG-AGC-AUU-CUU-C-3’. SiCTRL: sense strand = 5´-
UGC-GCU-ACG-AUC-GAC-GAU-G-3´; antisense strand = 5´-CAU-CGU-CGA-UCG-UAG-
CGC-A-3´. For fluorescence experiments, the siCTRL duplex was labeled with a Cy5 dye at 
the 5’ end of the sense strand (siCy5). The fluorescent modifications were performed and 
verified by Eurogentec. The concentration of the siRNA stock solutions in nuclease-free water 
(Ambion®-Life Technologies, Ghent, Belgium) was calculated from absorption measurements 
at 260 nm (1 0D260 = 40 µg mL-1) with a Nanodrop 2000 spectrophotometer (Thermo Fisher 
Scientific, Rockford, USA). 
 
2.2. Synthesis of dextran nanogels and loading with siRNA 
Cationic dextran nanogels were prepared using an inverse mini-emulsion photopolymerization 
method as reported previously [17]. Dextran hydroxyethyl methacrylate (dex-HEMA) with a 
degree of substitution of 5.2 [23] was selected for the preparation of the dextran nanogels based 
on previous work [24]. 
Briefly, 150 mg of dex-HEMA was dissolved in a solution containing 97.5 µL irgacure 2959 
(10 mg mL-1 in water; Sigma-Aldrich, Bornem, Belgium), 180 µL nuclease-free water and 
195 µL of a cationic methacrylate monomer, [2-(methacryloyloxy)-ethyl] trimethylammonium 
chloride (TMAEMA, 80 wt% solution in water; Sigma-Aldrich). The obtained dex-HEMA 
solution was emulsified in 5 mL of mineral oil (Sigma-Aldrich), supplemented with the 
surfactant ABIL EM 90 (0.5 mL) (Evonik Goldschmidt GmbH, Essen, Germany), through 
ultrasonication (90 s, amplitude 15 %; Branson Digital Sonifier®, Danbury, USA). The formed 
emulsion nanodroplets were immediately cross-linked by UV irradiation (900 s, Bluepoint 2.1 
UV source, Hönle UV technology, Gräfelfing, Germany) under cooling (4°C). The resulting 
dex-HEMA-co-TMAEMA nanogels, hereafter abbreviated as NGs, were collected by 
precipitation in acetone and washed four times with acetone:hexane (1:1). Traces of organic 
solvent were removed by vacuum evaporation and the pellet was redispersed in 5 mL nuclease-
free water. To assure long-term stability, the NGs were lyophilized and stored desiccated. 
Prior to use, a NG stock (10 mg mL-1) was prepared by dispersing a weighed amount of 
lyophilized particles in ice-cooled nuclease-free water, followed by short sonication (amplitude 
10 %, Branson Digital Sonifier®). The NG stock contained less than 0.5 EU mL-1 
lipopolysaccharide (LPS) as determined by the Endosafe®-PTSTM assay (Charles River 
International, Leco, Italy). To load NGs with siRNA, equal volumes of NG and siRNA dilutions 








2.3. Preparation of pulmonary surfactant-coated nanogels 
A commercially available pulmonary surfactant, derived from minced porcine lungs 
(Curosurf®; Chiesi Pharmaceuticals, Parma, Italy), was used to construct the lipid coat. 
Pulmonary surfactant-coated siRNA-loaded NGs (siNGs) were prepared as described 
previously [22]. Briefly, Curosurf® was incubated with siNGs for 10 min at 4 °C, allowing 
electrostatic interaction. The ratio of surfactant-to-NGs equaled 10 mg Curosurf® (total 
phospholipids) per mg NGs. After incubation, the surfactant shell was formed by high-energy 
sonication, using a probe sonicator (amplitude 10 %).  
 
2.4. Cryogenic transmission electron microscopy 
Coated NGs were formed according to the method described above. The ratio of surfactant to 
NGs equaled 7.5 mg Curosurf® per mg NGs. 2.5 µL of the different samples was placed on a 
glow discharged holey carbon coated grid (Quantifoil® R 3.5/1, Quantifoil Micro Tools GmbH, 
Grosslöbichau, Germany). The excess of liquid was blotted with a filter paper, reducing the 
droplet to a thin film. The samples were vitrified in liquid ethane, using a vitrobot (FEI, 
Eindhoven, The Netherlands) and stored in liquid nitrogen until observation. The grids were 
transferred to a cryo specimen holder type 626 (Gatan GmbH, München, Germany) and 
observed in a CM 120 cryo-electron microscope (Philips, Eindhoven, The Netherlands) 
operating at 120 keV. Images were recorded on a slow-scan CCD camera (Gatan GmbH) under 
low-dose conditions. 
 
2.5. Purification of the pulmonary surfactant-coated nanogels 
The surfactant-coated siNGs were separated from excess surfactant by centrifugation through 
a 7.5 wt% OptiPrepTM (Sigma-Aldrich) cushion for 30 min at 30000 g (L8-70M Centrifuge 
with SW55 Ti rotor; Beckman Coulter, Suarlée, Belgium). The supernatant, enclosing empty 
surfactant vesicles, was removed. The resulting pellet, containing the purified surfactant-coated 
NGs (abbreviated as coated NGs-P), was resuspended in nuclease-free water. Subsequently, 
equal volumes of the resuspended formulation and double-concentrated phosphate buffered 
saline (PBS; Gibco®-Life Technologies) were mixed, in order to obtain physiological salt 
concentrations.  
 
2.6. Nanoparticle concentration determined by fluorescence single particle tracking 
Fluorescence single particle tracking (fSPT) is a technique that monitors the diffusional 
movement of individual fluorescently labeled nanoparticles using a highly sensitive 
fluorescence microscope setup as described in [25]. Besides the size of nanoparticles, this 
technique also allows to accurately measure the absolute number concentrations of 
nanoparticles dispersed in complex biological fluids [26]. In our experiments, a swept-field 
confocal microscope (Eclipse Ti; Nikon, Brussels, Belgium) with a solid-state 125 mW 640 nm 
and 20 mW 488 nm laser (Agilent Technologies, Santa Clara, USA) laser was used to excite 
the fluorophores in samples mounted on the microscope equipped with a Plan Apo VC 100x 
1.4 NA oil immersion objective lens (Nikon). A fast and sensitive EMCCD camera (Ixon Ultra 
897; Andor Technology, South Windsor, USA) recorded high-speed movies of the individual 
particles diffusing in the dispersion. Particle trajectories were subsequently calculated using in-
house developed software [25].  
In this work, the technique was used to simultaneously determine the concentration of 
fluorescently-labeled siNGs and empty pulmonary surfactant present in the surfactant-coated 
siNG dispersion, before and after purification. Prior to use for siNG coating, Curosurf® was 
mixed with 2.5 wt% (of the total phospholipids) lipid-like dye DIO (InvitrogenTM – Life 
Technologies) in chloroform:methanol (2:1). A lipid film was formed by rotary evaporation of 
the organic solvents under vacuum at 37 °C. The dried lipid film was rehydrated in nuclease-
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free water under mechanical agitation. The NGs were loaded with Cy5-labeled siRNA (10 pmol 
per µg NG). A total of 5 µL of the thus obtained dual-labeled surfactant-coated siNGs was then 
applied between a microscope slide and a cover glass with a double-sided adhesive sticker of 
120 µm thickness in between (Secure-Seal Spacer, Molecular Probes, Leiden, The 
Netherlands). The microscope was always focused at ± 20 µm above the cover glass to avoid 
deviations from free diffusion. For each sample, 25 movies of approximately 200 frames each 
were recorded at different locations within the sample. 
 
2.7. Cell line and culture conditions 
All cell culture experiments in this study were conducted on murine alveolar macrophages 
(MH-S). The cells were grown in RPMI 1640 medium, supplemented with 2 mM glutamine, 
10 % fetal bovine serum (FBS), 100 U mL-1 penicillin/streptomycin, 0.05 mM 2-
mercaptoethanol, 0.01 M N-2-hydroxyethylpiperazine-N’-2-ethanesulfonic acid (HEPES), and 
1 mM sodium pyruvate. All materials were purchased from Gibco®-Life Technologies, except 
for the serum, which was delivered by HycloneTM (Thermo Fisher Scientific). The cells were 
cultured at 37 °C in a humidified atmosphere containing 5 % CO2. Cells were passed every 
3 days using 0.25 % trypsin/ethylenediamine-tetraacetic acid (EDTA) solution (Gibco®-Life 
Technologies) in order to maintain subconfluency. 
 
2.8. In vitro quantification of cellular internalization and gene silencing by flow cytometry 
Twenty-four hours before transfection, MH-S cells were seeded in 12-well plates (Greiner Bio-
One GmbH, Frickenhausen, Germany) at a density of 4x104 cells per cm2.  
To quantify the cellular internalization, NGs were loaded with different amounts of siRNA, 
labeled with 0.75 mol% Cy5. After five-fold dilution in Opti-MEM® (Gibco®-Life 
Technologies), resulting in a final NG concentration of 20 µg mL-1 and a final siRNA 
concentration of 100 nM, 10 nM or 1 nM, the samples were brought onto the cells. Following 
incubation (4 h), the cells were washed with PBS and incubated with dextran sulfate sodium 
salt (0.1 mg mL-1 in PBS) to remove surface bound fluorescence. Next, the cells were harvested 
by trypsinization (trypsin/EDTA 0.25 %) whose activity was halted by adding complete cell 
culture medium. Following centrifugation (7 min, 300 g), the cell pellet was resuspended in 
250 µL flow buffer (PBS supplemented with 1 % bovine serum albumin and 0.1 % sodium 
azide) and placed on ice until flow cytometric analysis. 
To determine the silencing potential of the different formulations, NGs were loaded with 
varying amounts of siCD45. The CD45 expression was normalized to that of cells treated with 
a negative control siRNA sequence (siCTRL). Upon 4 h of incubation, the cells were washed 
with PBS and 1 mL of culture medium was added. Two days post-transfection, the cells were 
detached with a non-enzymatic cell dissociation buffer (10 min incubation at 37°C). After 
centrifugation (7 min, 300 g), the cell pellet was resuspended in staining buffer (PBS 
supplemented with 5 % FBS). High-affinity Fc receptors were blocked by incubation with 
purified anti-mouse CD16/CD32 (BD Biosciences, Erembodegem, Belgium) for 15 min at 
4 °C. Subsequently, the cells were incubated with PerCP-CyTM 5.5 rat antimouse CD45 (BD 
Biosciences) diluted in staining buffer for 45 min at room temperature. Following three washing 
steps with 1 mL staining buffer, the cell pellet was resuspended in 250 µL flow buffer and 
placed on ice until flow cytometric analysis.  
A minimum of 104 cells was analyzed in each measurement, using a FACSCaliburTM flow 
cytometer (BD Biosciences). The fluorescence detector for Cy5-labeled siRNA and for PerCP-
CyTM 5.5 labeled antibody detects wavelengths of 661 nm (± 16 nm) and above 670 nm, 






Female BALB/c mice were purchased from Charles River International and housed on a 12 h 
light/dark schedule. All mice were 6 to 8 weeks old at the start of the experiments. All 
procedures involving animals were approved by the local Ghent University ethics committee. 
Mouse pharyngeal aspiration was used for pulmonary administration. Briefly, after 
anesthetization via an intraperitoneal injection of a ketamine/xylazine mixture, the mouse was 
placed in a near-vertical position. The animal’s tongue was extended with lined forceps, and 
80 µL of the nanoparticle dispersion was placed posterior of the pharynx. The tongue was held 
in position until the dispersion was inhaled into the lungs. Control mice were administered 
80 µL of PBS. 
 
2.10. Bronchoalveolar lavage 
At different time intervals upon aspiration, mice were sacrificed by intraperitoneal application 
of a lethal dose of Nembutal® (200 mg kg-1; Ceva, Brussels, Belgium). A lavage cannula was 
immediately placed into the trachea through a small incision. The lungs were flushed four times 
with 1 mL Ca2+- and Mg2+- free Hank’s balanced salt solution (HBSS; InvitrogenTM-Life 
Technologies), supplemented with 0.05 mM EDTA. The obtained bronchoalveolar lavage 
(BAL) was subsequently centrifuged, to separate the cellular fraction present in the lavage from 
the BAL fluid (BALF).  
 
2.11. Assessment of acute in vivo toxicity 
Dose-dependent acute local inflammatory responses were evaluated for NGs, surfactant-coated 
NGs, and purified surfactant-coated NGs (coated NGs-P). Importantly, in these experiments the 
mice were treated with unloaded nanoparticles, in order to exclude the influence of siRNA on 
the innate immune system and thus to assess the acute inflammatory features of the 
nanoparticles as such. Doses were adjusted by altering the concentration of the particles (i.e. 
1.25 mg mL-1; 2.5 mg mL-1, 3.75 mg mL-1). The aspirated volumes were held constant at 80 µL. 
Additionally, mice were treated with Curosurf® vesicles, at the highest dose present in the most 
concentrated surfactant-coated NG formulation (i.e. 3000 µg phospholipids). As a negative 
control, mice were treated with PBS. One day after aspiration, the BAL samples were isolated 
from the treated mice. Both the cytokine and chemokine expression levels in the BALF, and 
the cellular infiltration in the BAL, were determined.  
Protein levels of mouse TNF-α, IL-1α, IL-6, CXCL1, and MCP-1 in BALF were quantified 
with a Bioplex Suspension array system (Biorad, Hercules, USA) according to manufacturer’s 
specifications. The analytes were measured with a Luminex protein array reader and Bio-Plex 
manager software version 5.0 (Bio-Rad Laboratories), using recombinant standards (Bio-Rad 
Laboratories). For data analysis, a 5-parameter logistic curve fit was applied to each standard 
curve and sample. 
The total number of BAL cells was counted, after lysis of RBCs with ammonium potassium 
chloride lysis buffer, by use of a Bürker chamber (Brand GmbH, Wertheim, Germany). Trypan 
blue was added to exclude dead cells. The differential BAL cell counts were analyzed by flow 
cytometry. Cells, pre-incubated with Fc Block (purified anti-mouse CD16/CD32; BD 
Biosciences), were classified as monocytes, eosinophils, neutrophils, or lymphocytes based on 
forward and side scatter pattern and fluorescence intensities of anti-mouse CD3-Alexa488, 
SiglecF-PE, CD4-PerCP (all from BD Biosciences), CD11c-PE-TR (InvitrogenTM, Life 
Technologies) MHCII-v450, CD8-PE-Cy7 and CD11b-APC-eFluor780 (all from eBioscience; 
Vienna, Austria). Sytox Red (Molecular Probes®, Life Technologies) staining was performed 





2.12. Uptake in resident alveolar macrophages 
The ability of resident alveolar macrophages (rAM) to internalize NGs loaded with 
fluorescently-labeled siRNA (siCy5) was assessed by flow cytometry. Briefly, siCy5 was 
complexed with the lowest NG dose in previous experiment (100 µg) at a ratio of 1 pmol siCy5 
per µg NGs. Mice were treated with free siRNA, siNGs, surfactant-coated siNGs or surfactant-
coated siNGs-P (n=4). At various time points after treatment, BAL was collected as described 
above. First, high-affinity Fc receptors were blocked by incubation with purified anti-mouse 
CD16/CD32 (BD Biosciences) for 15 minutes at 4°C. Next, the rAM were selected based on 
their forward and side scatter pattern, intrinsic autofluorescence and their surface marker 
profile, using an antibody against CD11c (CD11c-PE-TR), SiglecF (SiglecF-PE) and Ly6C 
(Ly6C-v450; BD Biosciences). The samples were measured on a FACSLSRIITM flow 
cytometer (BD Biosciences). Data analysis was performed using the FlowJoTM analysis 
software (Treestar, Costa Mesa, USA). 
 
2.13. Silencing in resident alveolar macrophages 
The in vivo silencing potential of the different formulations in rAM was assessed on protein 
level, using flow cytometry, and on RNA level, using real-time quantitative PCR (qPCR). Here, 
mice were treated with 22.5 µg active siRNA, designed to selectively reduce CD45 expression 
(siCD45), or 22.5 µg negative control siRNA (siCTRL). 
To determine the gene expression on protein level, mice were treated with the same samples as 
described above (n=4, NG dose of 100 µg). BAL was collected after 24 h, 48 h, or 96 h and the 
CD45 expression profile in rAM was determined by fluorescently-labeled CD45 antibody 
(PerCP-CyTM 5.5 rat antimouse CD45; BD Biosciences).  
To evaluate the transcriptional level of the cd45 gene by qPCR, mice were treated with 
surfactant-coated siNGs (final NG dose = 100 µg). As a negative control, mice were treated 
with PBS. One day after the aspiration, the mice were sacrificed and the BAL was isolated. The 
alveolar macrophages were collected from BAL by the magnetic-activated cell sorter separation 
system using anti-CD11c microbeads (Miltenyi Biotec, Auburn, USA). RNA isolation from the 
alveolar macrophages was completed using an RNeasy Plus mini kit (Qiagen, Hilden, 
Germany) according to manufacturer’s protocol. cDNA was synthesized using a iScriptTM 
cDNA synthesis kit (Bio-Rad Laboratories). Real-time quantitative PCR (qPCR) was 
performed on a LightCycler 480 system using a qPCR kit for SYBR Green I (Roche Molecular 
Systems, Pleasanton, USA). Real-time qPCR amplification was performed in triplicate 
reactions under the following conditions: a pre-incubation step at 95°C for 5 min, followed by 
50 cycles at 95°C for 10 s and at 60°C for 30 s. The following primers were used: Murine 
cd45_1 forward primer = 5’-CAGAAACGCCTAAGCCTAGTTG-3’; reverse primer = 5’-
AGGCAAGTAGGGACACTTCATAG-3’. Murine cd45_2 forward primer = 5’-ATAT 
CGCGGTGTAAAACTCGTC-3’; reverse primer = 5’-TAGGCTTAGGCGTTTCTGGAA-3’. 
Murine rpl13a forward primer = 5’=-CCTGCTGCTCTCAAGGTTGTT-3’; reverse primer = 
5’-TGGCTGTCACTGCCTGGTACTT-3’. Murine tbp forward primer = 5’- TCTACCGTG 
AATCTTGGCTGT AAA-3’; reverse primer = 5’-TTCTCATGATGACTGCAGCAAA-3’. 
Murine b2m forward primer = 5’-ATGCACGCAGAAAGAAATAGCAA-3’; reverse primer 
= 5’-AGCTATCTAGGATATTTCCAATTTTTGAA-3’. Murine rpl13a, tbp and b2m mRNA 
was used as reference housekeeping gene for normalization [27]. All primers were purchased 
from InvitrogenTM (Life Technologies). The relative mRNA expression is presented by means 
of n-fold induction when compared with PBS-treated mice. 
 
2.14. Statistical analysis 
All data are presented as mean ± standard error (SEM). Presented data are representative for at 
least 2 independent experiments. Statistical analyses were performed by one- and two-way 
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ANOVA with Bonferroni correction, using GraphPad Prism software version 6. An unpaired t-
test was used to compare the transcriptional level of the cd45 gene, as determined by qPCR. 
 
3. Results 
3.1. Purification of the pulmonary surfactant-coated nanogels 
We recently demonstrated that the cellular delivery capacity of siRNA-loaded nanogels (siNGs) 
could be significantly enhanced by decorating them with a pulmonary surfactant (Curosurf®) 
shell [22]. To this end, both cationic siNGs and anionic crude pulmonary surfactant are mixed 
to allow electrostatic interaction, followed by high-energy sonication to induce fusion of the 
pulmonary surfactant on the siNG surface [22]. Cryo-TEM imaging of the pulmonary 
surfactant-coated siNGs revealed two coexisting nanostructures: (i) the hybrid nanoparticles 
consisting of a siNG core layered with a unilamellar pulmonary surfactant shell and (ii) an 
excess of empty pulmonary surfactant vesicles (Figure 1A). It is conceivable that this surplus 
of Curosurf® could affect the cellular delivery of siRNA and the inflammatory response upon 
pulmonary administration. Therefore, we sought to optimize a procedure to separate the 
pulmonary surfactant-coated siNGs from empty pulmonary surfactant vesicles. As 
schematically depicted in Figure 1B, the protocol involves high-speed centrifugation through 
a 7.5 wt% OptiPrepTM cushion of which the selected density slightly exceeds that of the empty 
surfactant vesicles. As a result the latter vesicles remain on top of the cushion upon 




Figure 1. (A) Cryogenic transmission electron microscopy images of the pulmonary surfactant-coated siRNA-
loaded nanogels (coated siNGs). The white arrows mark the pulmonary surfactant coat. The scale bar corresponds 
with 100 nm. (B) Scheme illustrating the different steps involved in the separation of the coated siNGs from the 
empty pulmonary surfactant vesicles. (1) The pre-formed siNGs interact with the unprocessed surfactant 
dispersion. Hereafter, phospholipid fusion onto the nanogel surface is induced via probe sonication. (2) The coated 
siNG dispersion is layered on top of a 7.5 wt% OptiPrepTM cushion. (3) The tubes are centrifuged at 30000 g 
during 30 min (4 °C). (4) The supernatant is removed, including the empty pulmonary surfactant vesicles on top 
of the OptiPrepTM layer. The pellet is resuspended in nuclease-free water and mixed in equal volumes with double 
concentrated PBS, to obtain the purified coated siNGs (Coated siNGs-P). (C and D) Particle number concentration 
of the coated siNGs loaded with red fluorescent siRNA (10 pmol per µg NG) (C, n=5) and the empty Curosurf® 
vesicles labeled with the lipid-like dye DIO (2.5 wt%) (D, n=3), determined by dual-color fluorescence single 
particle tracking. 
 
To assess the feasibility of this purification procedure, the concentration of both empty 
surfactant vesicles and surfactant-coated siNGs was determined before and after the 
centrifugation step, using fluorescence single particle tracking (fSPT). As described earlier, this 
technique allows accurate quantification of absolute number concentrations of fluorescently 
labeled nanoparticles in complex mixtures [25, 26]. To distinguish both particle types, 
Curosurf® was fluorescently labeled by insertion of the green fluorescent lipid-like dye DiO, 
while NGs were loaded with red fluorescent siRNA (siCy5). The dual-labeled nanoparticles 
were simultaneously illuminated by a 488 nm and 640 nm laser to allow quantification of both 
nanoparticle populations. We observed no significant loss of pulmonary surfactant-coated 
siNGs during the purification protocol (Figure 1C). Subtraction of the number of particles 
detected in the red channel (coated siNGs) from the number of particles detected in the green 
channel (coated siNGs and empty surfactant vesicles), yielded the concentration of the empty 
surfactant vesicles (Figure 1D). Importantly, it was shown that 67.2 % of the empty surfactant 
vesicles could be removed via this protocol. 
 
3.2. In vitro siRNA delivery to alveolar macrophages 
The capacity of the different nanoparticles to guide siRNA delivery to a murine alveolar 
macrophage cell line (MH-S) was evaluated. To this end, the cells were incubated with siNGs, 
surfactant-coated siNGs, or surfactant-coated siNGs after removal of free pulmonary surfactant 
vesicles (surfactant-coated siNGs-purified, abbreviated as coated siNGs-P). Free siRNA was 
included as a control and, as expected, no relevant internalization of free siCy5 by the cells 
could be detected (Figure 2A). Encapsulating the siRNAs in cationic siNGs markedly 
facilitated cellular uptake, in agreement with earlier reports on this formulation [17, 18]. The 
presence of a pulmonary surfactant outer shell significantly inhibited cellular uptake (Figure 
2A), which was also observed earlier in cultured lung cancer cells [22]. This is most likely 
attributed to the shielding of the siNG positive charge with anionic pulmonary surfactant, 
thereby precluding efficient electrostatic interaction with the macrophage cell membrane. 
In order to evaluate the in vitro gene silencing potential of the siRNA-loaded nanoparticles, 
protein tyrosine phosphatase receptor type C (CD45), which is expressed on the surface of all 
nucleated hematopoietic cell types, was selected as a model target. The data shown in Figure 
2B demonstrate a significantly lowered expression level of CD45 protein, reaching 60 % 
knockdown for the uncoated siNGs at the highest siRNA dose. Note that the CD45 knockdown 
was only slightly reduced in the presence of the surfactant shell. Importantly, given the ten-fold 
reduction in intracellular siRNA dose upon coating, as shown in Figure 2A, it can be 






Figure 2. Cellular uptake and gene silencing potential of the different formulations in a murine alveolar 
macrophage cell line (MH-S), determined by flow cytometry. Evaluation of cellular uptake (A) and CD45 gene 
silencing potential (B) of free siRNA (white), siRNA complexed with nanogels (siNGs; black), pulmonary 
surfactant-coated siNGs (light gray) or purified pulmonary surfactant-coated siNGs (coated siNGs-P; dark gray), 
as a function of siRNA concentration. The experiments were performed with a fixed nanogel concentration (20 µg 
mL-1). For the uptake experiments fluorescent siRNA was used (0.75 mol% Cy5-labeled). To determine the 
percentage CD45 expression, the CD45 expression of cells treated with active siRNA (siCD45) was normalized 
to that of cells treated with control siRNA (siCTRL). Data points represent geometric mean fluorescence intensities 
± standard error (n=3). 
 
3.3. Acute inflammatory effect in murine lungs 
Since the pulmonary application of nanoparticles might induce an acute inflammatory response 
in the lungs [28], it is of particular importance to evaluate the in vivo pro-inflammatory effects 
of novel nanocarriers.  
To this end, BALB/c mice were treated with increasing doses of the different aforementioned 
nanocarriers via pharyngeal aspiration. After 24 h, the bronchoalveolar lavage fluid (BALF) 
was collected and the levels of the pro-inflammatory cytokines IL-1α, IL-6 and TNF-α were 
quantified along with the levels of the chemokines CXCL-1 and MCP-1 (Figure 3). 
In general, the aspiration of nanoparticles significantly enhanced the expression of all cytokines 
and chemokines in BALF, except for TNF-α, compared to the expression levels in placebo 
(PBS)-treated mice. Furthermore, the NGs elicited a dose-dependent response, showing 
elevated levels of most cytokines and chemokines at mounting NG doses (Figure S1_A). 
Importantly, this acute pro-inflammatory response could partially be reduced by shielding the 
NG surface with the pulmonary surfactant shell (Figure S1_B). Of note, aspiration of empty 
Curosurf® vesicles induced negligible secretion of inflammatory mediators. The latter 
observation likely also explains the comparable cytokine/chemokine expression levels for both 




Figure 3. Cytokine (A-C) and chemokine (D,E) concentrations in bronchoalveolar lavage fluid of mice 24 h 
after treatment with nanogels (NGs), pulmonary surfactant-coated NGs or purified coated NGs (coated 
NGs-P). Mice were treated with increasing NG doses: 100 µg (black), 200 µg (light gray), or 300 µg (gray). 
Additionally, mice were treated with surfactant (Curosurf®) vesicles (CS). The aspirated dose equals the surfactant 
dose present in the most concentrated coated formulations (3000 µg of total phospholipids). As a negative control, 
mice were treated with PBS. The protein concentrations were measured using a Bio-Plex suspension array system, 
according to manufacturer’s instructions. Data points represent average values ± standard error (n=4). The asterisks 
represent the statistical significance compared to PBS-treated mice (*p ≤ 0.05, **p ≤ 0.01, ***p ≤  0.001, 
****p ≤ 0.0001).  
 
Next, we evaluated the impact of the nanoparticles on the recruitment of inflammatory cells in 
the bronchoalveolar lavage (BAL). To this end, the total cell numbers in BAL 24 h after 
aspiration of increasing doses of nanoparticles were determined (Figure 4A). Contrarily to the 
elevated cytokine and chemokine levels, aspiration of NGs did not induce inflammatory cell 
infiltration even at the highest dose. However, coating of the NGs with surfactant elicited 
inflammatory cell recruitment at the highest dose of 300 µg NG. Likely, this inflammatory 
response resulted from the presence of free Curosurf® vesicles as indicated by the pronounced 
increment in bronchoalveolar inflammatory cell number observed following administration of 
Curosurf® vesicles alone and the lack of inflammatory cell recruitment when free surfactant 
vesicles were partially removed from the formulation (coated NGs-P).  
12 
 
In all instances, the dominant inflammatory cell type recruited to the alveolar compartment 
were neutrophils as illustrated in Figure 4B, showing the cell-type specific composition of the 
inflammatory cell infiltrate elicited by the lowest NG doses. 
Figure 4. Cellular infiltration in the bronchoalveolar lavage (BAL) of mice treated with nanogels (NGs), 
pulmonary surfactant-coated NGs or purified coated NGs (coated NGs-P). As a negative control, mice were 
treated with PBS. (A) Total cell infiltration in BAL in response to the aspiration of increasing NG doses: 100 µg 
(green), 200 µg (blue), or 300 µg (red). The aspirated dose of Curosurf® vesicles (CS; gray) equals the dose present 
in the most concentrated coated formulations (3000 µg of total phospholipids). The individual data points and their 
corresponding average values were illustrated (n=4). (B) The differential cellular composition in BAL of mice 
treated with the different nanoparticles at the lowest NG dose (100 µg). Flow cytometric analysis differentiated 
monocytes (white), neutrophils (black), eosinophils (light gray), and T-cells (dark gray). Data points represent 
average values ± standard error (n=4). The asterisks represent the statistical significance compared to PBS-treated 
mice (*p ≤ 0.05, **p ≤ 0.01, ***p ≤  0.001, ****p ≤ 0.0001). 
 
3.4. In vivo siRNA delivery to murine resident alveolar macrophages  
Given the promising in vitro results, we sought to evaluate the potential of our formulations 
toward in vivo pulmonary siRNA delivery to resident alveolar macrophages (rAM). To evaluate 
this, the different nanoparticles, loaded with Cy5-labeled siRNA, were administered into the 
lungs of BALB/c mice via pharyngeal aspiration. The lowest NG doses (100 µg) were applied 
to minimize acute pulmonary inflammatory responses. BAL was collected at the indicated time 
points and analyzed by flow cytometry (Figure 5). rAM constitute the main phagocytic cell 
type in the bronchoalveolar lumen and were identified on the basis of their intrinsic high 
autofluorescence and the expression of the surface marker CD11c (Figure 5A). Already 4 h 
after treatment with siNGs and surfactant-coated siNGs, nearly all rAM had internalized Cy5-
labeled siRNA. At 72 h, still 70% of the rAM population stained positive for Cy5-labeled 
siRNA upon aspiration of the surfactant-coated NGs, while a sharp drop to only 30% Cy5-
positive rAM was observed after treatment with the uncoated siNGs (Figure 5A). Importantly, 
only a negligible percentage of Cy5-positive rAM were found in the lungs of mice treated with 
free siRNA. 
Analysis of the Cy5 fluorescence intensities in rAM showed that, contrarily to the in vitro 
results, the surfactant shell did not cause an equivalent reduction in cellular internalization of 
siNGs in vivo (Figure 5B). Thus, in correspondence with the high percentages of Cy5-positive 
rAM at 4h and 24h, both siNGs and surfactant-coated siNGs yielded comparable levels of siCy5 
uptake by the rAM. Strikingly, removal of excess free surfactant vesicles negatively impacted 
both the percentage of siCy5-positive rAM (Figure 5A) as the level of siCy5 uptake (Figure 
5B). Yet, at the late 72h time-point, the differences between both coated formulations leveled 
off, both now showing an almost four-fold higher Cy5 fluorescence and a two-fold higher 
percentage of Cy5-positive rAM compared to rAM of mice treated with uncoated siNGs. This 
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result strongly points to an involvement of exogenous pulmonary surfactant in prolonging the 
residence time in the lung of the administered siRNA, hereby stabilizing or even increasing 
with time the levels of siCy5 uptake by rAM. 
 
Figure 5. Flow cytometric analysis of the uptake of fluorescent siRNA (siCy5) by resident alveolar 
macrophages (rAM) at different time points after aspiration. (A) Dot plots of gated rAM indicate the 
percentage of Cy5-positive rAM in the bronchoalveolar lavage 4 h, 24 h, and 72 h after treatment with free siRNA 
or siRNA complexed with nanogels (siNGs), coated siNGs, or purified coated siNGs (coated siNGs-P). The 
respective percentages are depicted in each quadrant. (B) Geometric mean fluorescence intensities were quantified 
in rAM of mice treated with siNGs (black), coated siNGs (light gray), coated siNGs-P (dark gray), or free siRNA 
(white). Data represent average values ± standard error (n=4, *p ≤ 0.05, **p ≤ 0.01, ***p ≤  0.001). 
 
3.5. In vivo gene silencing in resident alveolar macrophages 
Having quantified the cellular internalization of Cy5-labeled siRNA, we next examined the 
efficiency of the different nanoparticle formulations to deliver functional siRNA, capable of 
mediating gene knockdown in rAM. Protein levels of the model target CD45 were analyzed by 
flow cytometry as a function of time following aspiration of the different nanoparticle 
formulations (Figure 6). Notably, the pulmonary delivery of negative control siRNA (siCTRL), 
either as free siRNA or complexed with the nanoparticles, resulted in elevated expression levels 
of CD45 protein by rAM 24 h and 48 h after treatment (Figure 6A and 6B). This effect even 
persisted for 96 h in mice treated with surfactant-coated siNGs and surfactant-coated siNGs-P 
(Figure 6C). This increased CD45 protein density on the surface of rAM is a known 
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phenomenon for hematopoietic cells, which control their CD45 phosphatase activity in 
response to different stimuli by altering CD45 protein levels [29]. Importantly, two days after 
treatment, only pulmonary delivery of surfactant-coated siNGs, loaded with active siCD45, 
resulted in a significant reduction of this CD45 upregulation, as compared to siCTRL (Figure 
6B). At 96 h after treatment with surfactant-coated siNGs and surfactant-coated siNGs-P 
containing siCD45, CD45 expression levels decreased further to baseline levels (PBS), thus 
completely countering the treatment-induced increment in CD45 expression (Figure 6C). 
 
Figure 6. CD45 gene expression in resident alveolar macrophages (rAM) at different time points after 
treatment, determined by flow cytometry. Geometric mean fluorescence intensities of PerCP-Cy5.5-labeled 
CD45 antibodies were quantified in rAM of mice 24 h (A), 48 h (B), or 96 h (C) upon aspiration. The mice were 
treated with free siRNA, siRNA complexed with nanogels (siNGs), coated siNGs, or purified coated siNGs (coated 
siNGs-P). Both negative control siRNA sequences (siCTRL, dark gray), as active siRNA designed to selectively 
target CD45 (siCD45, light gray) were used. The data are represented in a box-and-whisker plot. The box extends 
from the 25th to 75th percentiles. The line in the middle of the box is plotted at the median. The whiskers go from 




Since CD45 is a protein with a slow cell surface turnover, stable proteins residing at the plasma 
membrane could obscure the magnitude of the RNAi effect at the post-transcriptional level [29]. 
Therefore, we next aimed to determine CD45 silencing by quantifying cd45 mRNA transcript 
levels in BAL-isolated rAM from treated mice. Given that our flow cytometric analysis already 
identified surfactant-coated siNGs as the most promising delivery system, we chose to focus 
only on this formulation. The transcriptional status of the cd45 gene was evaluated by real-time 
quantitative polymerase chain reaction (RT-qPCR) one day after treatment. As shown in Figure 
7, no elevated levels of cd45 mRNA after treatment with surfactant-coated siNGs, loaded with 
siCTRL, could be detected in comparison to mRNA levels in PBS-treated mice. However, 
inhalation therapy with the surfactant-coated siNGs evoked an impressive and sequence-
specific reduction in cd45 mRNA, reaching up to 70 % knockdown. 
Together, these results clearly show that pulmonary surfactant-coated siNGs successfully 
delivered active siRNA to rAM in vivo. 
 
Figure 7. Transcriptional level of CD45 in resident alveolar macrophages of mice treated with coated 
siRNA-loaded nanogels (coated siNGs) 24 h after aspiration, determined by real-time quantitative 
polymerase chain reaction (qPCR) analysis. Results are given as the n-fold induction when compared with PBS-
treated mice, for both CD45 primers used in the real-time qPCR amplification. The graph is a summary of two 
independent experiments. A minimum of 8 animals per group was necessary to achieve sufficient RNA 




Resident alveolar macrophages (rAM) are attractive targets for siRNA inhalation therapy due 
to their prominent role in multiple respiratory disorders, such as cystic fibrosis, asthma, 
tuberculosis, and chronic obstructive pulmonary disease [6, 7]. 
Following successful in vitro siRNA delivery to non-small cell lung cancer cells with 
pulmonary surfactant-coated siNGs [22], in this study we aimed to test the in vivo delivery 
potential of this core-shell nanoparticle to rAM in mice via pulmonary administration. 
Remarkably, we found a striking difference in the uptake of siRNA by rAM between in vivo 
and in vitro conditions. In vitro, internalization of cationic siNGs in a murine alveolar 
macrophage cell line (MH-S) was significantly suppressed by the presence of the anionic 
pulmonary surfactant shell, likely due to electrostatic repulsion by the negatively charged cell 
surface [18]. In contrast, following pharyngeal aspiration in BALB/c mice, both coated and 
uncoated siNGs were equally well internalized by rAM up to 24 h post-aspiration. This can 
possibly be attributed to the adsorption of negatively charged components from the endogenous 
alveolar surfactant onto the surface of the uncoated siNGs, as already illustrated in the literature 
for other types of nanoparticles [30, 31]. The cd 45 gene was selected as a model target gene to 
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assess the RNAi effect [32]. Strikingly, despite the high intracellular siRNA doses in rAM 
obtained with both uncoated and surfactant-coated siNGs, only the latter were able to induce a 
significant CD45 knockdown in rAM. On the other hand, the removal of excess surfactant 
vesicles had a negative impact on the gene silencing potential, which could possibly be related 
to the significantly lower intracellular siRNA levels in rAM of mice treated with the purified 
formulation at the early time points (4 h and 24 h). Notably, the surfactant-coated siNGs were 
able to induce an effective siRNA-mediated gene knockdown, reaching 70 % knockdown in 
the difficult to transfect rAM, at a lower instilled siRNA dose compared to earlier work [14]. 
Together with our in vitro findings in MH-S cells, where a strong downregulation of CD45 
expression was maintained despite the hampered cellular uptake, these results jointly hint 
toward a beneficial effect of the pulmonary surfactant on cellular siRNA delivery. However, 
the exact mechanism via which the pulmonary surfactant shell promotes delivery is not yet 
clear.  
The benefit of a delivery vehicle for pulmonary administration of siRNA has been a subject of 
controversial discussion. In different pre-clinical models, a successful delivery in the 
respiratory tract of siRNA in the absence of a nanocarrier has been documented [33-35]. 
Moreover, promising results were obtained upon inhalation of free siRNA in human clinical 
trials for the treatment of patients infected with respiratory syncytial virus [36]. However, recent 
publications have clearly demonstrated the benefit of nanocarriers for siRNA inhalation therapy 
[9, 32, 37]. This was confirmed by our work, as the aspiration of free siRNA in the 
bronchoalveolar lumen of BALB/c mice resulted in negligible siRNA internalization by rAM 
and hence also failed to elicit a gene silencing effect. This observation underscores that in order 
to achieve delivery of siRNA to rAM, the siRNA should be formulated in an appropriate carrier, 
preferably in the nanometer range [11]. 
It is known from the literature that pulmonary administration of nanoparticles may trigger an 
acute local inflammatory response [28, 38]. Therefore, we assessed the levels of pro-
inflammatory cytokines and chemokines in the bronchoalveolar lavage as well as the infiltration 
of inflammatory cells one day following pharyngeal aspiration of our nanoparticles, focusing 
on the role of the exogenous surfactant. Our results clearly revealed that excess of clinically 
approved pulmonary surfactant (Curosurf®) promoted a significant, yet conflicting impact on 
both the pro-inflammatory secretions and the cellular infiltrations.  
Although it is conceivable that the expression levels of inflammatory mediators can change as 
a function of time [14], we clearly observed that the decoration of NGs with a pulmonary 
surfactant outer layer already significantly reduced the acute cytokine and chemokine responses 
evoked by bare cationic NGs. Moreover, comparable expression levels were observed for both 
surfactant-coated NGs and purified surfactant-coated NGs corroborating the negligible pro-
inflammatory responses upon aspiration of empty Curosurf® vesicles, which is in agreement 
with earlier reports [39]. In contrast, cellular infiltration upon aspiration of surfactant-coated 
NGs at the highest NG dose was significantly increased compared to uncoated NGs, and the 
partial removal of excess surfactant from the formulation again alleviated this response. Also 
here, the latter can be correlated to the high cellular infiltrations detected upon the local 




Achieving safe and efficient gene silencing in the lung following pulmonary administration 
remains a challenging task. In this study, we identified pulmonary surfactant-coated dextran 
nanogels, consisting of a siRNA-loaded nanogel (siNG) core and a pulmonary surfactant 
(Curosurf®) outer shell, as a promising siRNA delivery system for this purpose. Pharyngeal 
aspiration of surfactant-coated siNGs provoked only a mild inflammatory cytokine response 
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and neutrophil infiltration in the bronchoalveolar lumen of BALB/c mice, but efficiently 
delivered siRNA to resident alveolar macrophages (rAM). The latter resulted in a substantial 
gene knockdown in rAM, which are notoriously difficult to transfect, with a relatively low 
siRNA dose (~1 mg kg-1). Future research will be focused on evaluating biodistribution, toxicity 
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